Introducing GoNitro™ (nitroglycerin) sublingual powder:

the first and only short-acting nitrate powder in a single-dose packet, proven to provide fast relief from the pain of angina attacks.1

dots-bulletMany patients are not adequately protected from angina.2,3 See the statistics gonitro-circle-arrow

dots-bulletNew GoNitro powder absorbs quickly and works fast.4 Learn more  gonitro-circle-arrow

dots-bulletNow you can help protect your patients anywhere. See how gonitro-circle-arrow

INDICATION
GoNitro is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

The unmet need in stable ischemic heart disease

According to the 2012 Stable Ischemic Heart Disease (SIHD) Guidelines, all patients with SIHD should be prescribed sublingual nitroglycerin for immediate relief of angina.5

Ready to learn more about a new solution?  Read on gonitro-circle-arrow

INDICATION
GoNitro™ (nitroglycerin) sublingual powder is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

The powder that protects

GoNitro™ (nitroglycerin) sublingual powder is the first and only sublingual nitroglycerin powder packet available for acute angina and angina prophylaxis.1 The convenient packaging means GoNitro fits easily into your patients’ busy lives.

tap-tear-tip-hcp

Easy to open8: just tap, tear, and tip under the tongue. Please see the full Instructions for Use.

Convenient to carry
Small, thin, single-dose packets patients can store virtually anywhere at room temperature.

Individually packaged
Packets are available in boxes of 36, and individual packets can easily fit in a pocket, wallet, or purse. Each packet includes its expiration date—up to 24 months from the date of manufacture.

one-notch-packet-transparency

INDICATION
GoNitro is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

Watch the administration video

GoNitro™ efficacy and absorption

GoNitro™ (nitroglycerin) sublingual powder represents a new generation of fast-absorbing, short-acting nitrates. In a randomized, double-blind, single-dose 5-period cross-over study of 51 patients with exertional angina pectoris, significant dose-related increases in exercise tolerance, time to onset of angina, and ST-segment depression were seen following doses of 200 to 1600 mcg of GoNitro, compared with placebo.1

GoNitro dissolves quickly for fast absorption. A clinical study demonstrated higher and faster mucosal absorption for GoNitro powder, compared with sublingual spray.9

In a controlled study with healthy volunteers, GoNitro bioavailability was on average 45% higher than that of nitroglycerin sublingual spray, and reached the same plasma concentration 96 seconds faster.9

GoNitro resulted in higher and faster absorption than sublingual spray9

INDICATION
GoNitro is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

Additional benefits of GoNitro™

gonitro-clock-icon

Potency when it counts: GoNitro (nitroglycerin) sublingual powder packets maintain proven potency up to their expiration date from time of manufacture—as long as 24 months.

gonitro-card-icon

Single-dose, foil-lined packets provide stability and protect GoNitro from exposure to light, air, and water. Can be stored at room temperature (68°F to 77°F, with excursions permitted between 41°F to 104°F).

INDICATION
GoNitro is a nitrate vasodilator indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.

Convenient concierge service delivers GoNitro™ to your patients

Espero Pharmaceuticals and Express Drugs & Surgicals offer GoNitro Rx Direct—a free service that makes it easy for your patients to fill their prescriptions for GoNitro™ (nitroglycerin) sublingual powder. This program ensures cost effectiveness, coverage help, and fast, free, home delivery.

Rx Direct offers benefits for you and your patients:

• Assurance that GoNitro will always be in stock
• Automatically applied co-pay savings—eligible patients pay as little as $0
Free delivery within 3 hours for local patients and free overnight delivery for non-local patients
• Your office works with one pharmacy that is familiar with GoNitro
• Express Drugs will provide prior authorization assistance when required
Patient assistance is available if patients meet certain criteria

 

Important Safety Information

GoNitro™ (nitroglycerin) sublingual powder should not be used if you are taking medications for erectile dysfunction, such as avanafil, sildenafil, tadalafil, or vardenafil. Using GoNitro with these products may cause low blood pressure (hypotension), fainting, or heart attack.

Do not use GoNitro if you are taking soluble guanylate cyclase (sGC) stimulators, such as riociguat. Using GoNitro with these products may cause low blood pressure (hypotension).

GoNitro should not be used if you have anemia.

GoNitro should not be used in patients with increased intracranial pressure. Talk to your doctor if you had a cerebral hemorrhage or traumatic brain injury before taking GoNitro.

GoNitro should not be used if you have acute circulatory failure or shock.

GoNitro should not be used if you are allergic to nitroglycerin, other nitrates or nitrites or any excipient.

You might develop a tolerance to this drug or to other nitrates and nitrites. Only the smallest number of doses required for effective relief of the acute angina attack or prevention of an attack should be used.

You should use nitroglycerin with caution in the early days after a heart attack and it may aggravate the angina caused by a condition known as hypertrophic cardiomyopathy. Increased hypotension, mainly when standing upright, may occur even with small doses of nitroglycerin and may result in slow heart beat and increased angina. It should be used with caution if you are dehydrated due to drug therapy or if you have low blood pressure.

Headache is the most reported side effect and may be severe and persistent. Other side effects that have been reported are dizziness, numbness and tingling of the skin, skin scaling and rashes, drowsiness, nausea, increased heart rate.

Click [English PI] for full Prescribing Information or use links on top of page.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

References: 1. GoNitro [package insert]. Jacksonville, FL: Espero Pharmaceuticals and G. Pohl-Boskamp GmbH & Co. KG; 2016. 2. Singer N. FDA says millions got unapproved heart pills. New York Times. March 26, 2010. 3. Yilmaz OC, Keskin G, Cuglan B, et al. Frequency of sublingual nitroglycerin prescription in patients with coronary artery disease and angina and awareness of patients about the shelf life of the drug. Türk Kardiyol Dern Arş. 2011;39(6):469-473. 4. Data on file, Bioavailability. Espero Pharmaceuticals; 2016. 5. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60(24):e44-e164. 6. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Committee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2015; doi:10.1161/CIR0000000000000350. 7. Boden WE, Padala SK, Cabral KP. Role of short-acting nitroglycerin in the management of ischemic heart disease. Drug Des Devel Ther. 2015;9:4793-4805. 8. Data on file, Packaging Study 1. Espero Pharmaceuticals; 2016. 9. Data on file, Packaging Study 2. Espero Pharmaceuticals; 2016.

IMPORTANT SAFETY INFORMATION  —  GoNitro™ (nitroglycerin) sublingual powder should not be used if you are taking medications for erectile dysfunction, such as avanafil, sildenafil, tadalafil, or vardenafil. Using GoNitro with these products may cause low blood pressure (hypotension), fainting, or heart attack. For additional Important Safety Information please click here.